Rotigotine for the treatment of Parkinson's disease

John C. Morgan, Kapil D. Sethi

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.

Original languageEnglish (US)
Pages (from-to)1275-1282
Number of pages8
JournalExpert Review of Neurotherapeutics
Volume6
Issue number9
DOIs
StatePublished - Sep 1 2006

Fingerprint

Parkinson Disease
Dopamine Agonists
Levodopa
Therapeutics
Transdermal Patch
Apomorphine
Patient Compliance
N 0437
Clinical Trials
Lipids
Injections

Keywords

  • Continuous dopaminergic stimulation
  • Dopamine agonist
  • N-0437
  • N-0923
  • Parkinson's disease
  • Rotigotine
  • Transdermal patch

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Rotigotine for the treatment of Parkinson's disease. / Morgan, John C.; Sethi, Kapil D.

In: Expert Review of Neurotherapeutics, Vol. 6, No. 9, 01.09.2006, p. 1275-1282.

Research output: Contribution to journalReview article

@article{01e7909511ac4f8ebb34601e87a8be66,
title = "Rotigotine for the treatment of Parkinson's disease",
abstract = "Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.",
keywords = "Continuous dopaminergic stimulation, Dopamine agonist, N-0437, N-0923, Parkinson's disease, Rotigotine, Transdermal patch",
author = "Morgan, {John C.} and Sethi, {Kapil D.}",
year = "2006",
month = "9",
day = "1",
doi = "10.1586/14737175.6.9.1275",
language = "English (US)",
volume = "6",
pages = "1275--1282",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Rotigotine for the treatment of Parkinson's disease

AU - Morgan, John C.

AU - Sethi, Kapil D.

PY - 2006/9/1

Y1 - 2006/9/1

N2 - Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.

AB - Dopaminergic therapies, including levodopa and dopamine agonists, are the mainstays of therapy in Parkinson's disease. With the exception of the injectable short-acting dopamine agonist apomorphine, there is no other widely available non-oral dopaminergic therapy. Rotigotine is a lipid-soluble, non-ergot, D3, D2, D1 dopamine receptor agonist that has demonstrated efficacy as an alternative therapeutic option in both early and advanced Parkinson's disease. More importantly, it is uniquely formulated as a transdermal patch delivery system allowing for continuous, once-daily administration and better patient compliance. Preclinical and clinical trials have shown rotigotine to be a well-tolerated and effective treatment for early-stage Parkinson's disease. Rotigotine has also shown promise as adjunctive therapy with levodopa for the treatment of advanced Parkinson's disease.

KW - Continuous dopaminergic stimulation

KW - Dopamine agonist

KW - N-0437

KW - N-0923

KW - Parkinson's disease

KW - Rotigotine

KW - Transdermal patch

UR - http://www.scopus.com/inward/record.url?scp=33750079581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750079581&partnerID=8YFLogxK

U2 - 10.1586/14737175.6.9.1275

DO - 10.1586/14737175.6.9.1275

M3 - Review article

C2 - 17009915

AN - SCOPUS:33750079581

VL - 6

SP - 1275

EP - 1282

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 9

ER -